IPN Ipsen SA

IPSEN - Buy-back programme - Art 5 of MAR - Week 39 - 2025

IPSEN - Buy-back programme - Art 5 of MAR - Week 39 - 2025

Aggregated presentation by day and by market



Statement of transactions in own shares from September 22nd to September 26th 2025


 

 

 

 

 

 

 
Name of the issue Identity code of the issuer

(Legal Entity Identifier) 		Day of the transaction Identity code of the financial instrument Total daily volume (in number of shares) Daily weighted average purchase price of the shares Market (MIC Code)
IPSEN 549300M6SGDPB4Z94P11 22/09/2025 FR0010259150 300 115,90 AQEU
IPSEN 549300M6SGDPB4Z94P11 22/09/2025 FR0010259150 600 116,30 CCXE
IPSEN 549300M6SGDPB4Z94P11 22/09/2025 FR0010259150 300 116,20 TQEX
IPSEN 549300M6SGDPB4Z94P11 22/09/2025 FR0010259150 3400 115,85629 XPAR
IPSEN 549300M6SGDPB4Z94P11 23/09/2025 FR0010259150 275 112,62727 AQEU
IPSEN 549300M6SGDPB4Z94P11 23/09/2025 FR0010259150 1167 113,15596 CCXE
IPSEN 549300M6SGDPB4Z94P11 23/09/2025 FR0010259150 235 112,64681 TQEX
IPSEN 549300M6SGDPB4Z94P11 23/09/2025 FR0010259150 2923 113,84872 XPAR
IPSEN 549300M6SGDPB4Z94P11 24/09/2025 FR0010259150 185 115,08649 AQEU
IPSEN 549300M6SGDPB4Z94P11 24/09/2025 FR0010259150 1013 114,95716 CCXE
IPSEN 549300M6SGDPB4Z94P11 24/09/2025 FR0010259150 148 114,99797 TQEX
IPSEN 549300M6SGDPB4Z94P11 24/09/2025 FR0010259150 3254 115,17560 XPAR
IPSEN 549300M6SGDPB4Z94P11 25/09/2025 FR0010259150 290 111,80 AQEU
IPSEN 549300M6SGDPB4Z94P11 25/09/2025 FR0010259150 1625 111,78258 CCXE
IPSEN 549300M6SGDPB4Z94P11 25/09/2025 FR0010259150 248 111,86774 TQEX
IPSEN 549300M6SGDPB4Z94P11 25/09/2025 FR0010259150 2637 112,50076 XPAR
IPSEN 549300M6SGDPB4Z94P11 26/09/2025 FR0010259150 124 110,76935 AQEU
IPSEN 549300M6SGDPB4Z94P11 26/09/2025 FR0010259150 3476 111,10964 XPAR
        22200 113,67438  

Attachment



EN
30/09/2025

Underlying

IPNIpsen SA

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Ipsen SA

 PRESS RELEASE
Free
IPN IPSEN SA

Ipsen receives positive CHMP opinion for Ojemda® for the treatment as ...

Ipsen receives positive CHMP opinion for Ojemda® for the treatment as monotherapy of children with relapsed or refractory BRAF-altered pediatric low-grade glioma If approved, Ojemda® (tovorafenib) is expected to be the first and only targeted medicine in European Union for children with relapsed or refractory BRAF-altered pediatric low-grade glioma, irrespective of the type of BRAF alterationiThe decision is based on data from the pivotal Phase II FIREFLY-1 study which demonstrated clinically meaningful and durable tumor responses with a positive impact on children’s livesii PARIS, FRANCE,...

February 27, 2026 1 EN
 PRESS RELEASE
Free
IPN IPSEN SA

Ipsen reçoit un avis positif du CHMP pour Ojemda® en monothérapie pour...

Ipsen reçoit un avis positif du CHMP pour Ojemda® en monothérapie pour le traitement des enfants atteints de gliome pédiatrique de bas grade en rechute ou réfractaire, avec altération de BRAF S'il est approuvé, Ojemda® (tovorafénib) devrait devenir la première et la seule thérapie ciblée dans l’Union européennepour les enfants atteints d’un gliome pédiatrique de bas grade en rechute ou réfractaire avec altération de BRAF, quel que soit le type d’altération BRAF.iLa décision s’appuie sur les données de l’étude pivot de Phase II FIREFLY1, qui a démontré des réponses tumorales urables et clini...

February 27, 2026 1 EN
Free Trial
IPN IPSEN SA

Ipsen: 1 director

A director at Ipsen sold 3,800 shares at 158.200EUR and the significance rating of the trade was 65/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing C...

02/24/26 February 24, 2026 1 EN
 PRESS RELEASE
Free
IPN IPSEN SA

Ipsen S.A. publishes its 2025 Consolidated Financial Statements

Ipsen S.A. publishes its 2025 Consolidated Financial Statements Ipsen S.A. publishes its 2025 Consolidated Financial Statements Attachment

February 19, 2026 1 EN
 PRESS RELEASE
Free
IPN IPSEN SA

Ipsen S.A. publie ses comptes consolidés 2025

Ipsen S.A. publie ses comptes consolidés 2025 Ipsen S.A. publie ses comptes consolidés 2025 Pièce jointe

February 19, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch